Optiscan Imaging (ASX:OIL) said it has completed the first prototype to collect images from the gastrointestinal tract (GI) and has started a pre-clinical study with the University Medical Centre of the Johannes Gutenberg University Mainz, Germany, in a Monday filing with the Australian bourse.
The study is aimed at capturing images of the GI tract to diagnose and treat related diseases such as colon cancer, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.